Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics

中國醫藥大學機構典藏 China Medical University Repository, Taiwan > 台中附設醫院 > 期刊論文 > Item 310903500/30320

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.cmu.edu.tw/ir/handle/310903500/30320

题名:	Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics
作者:	Lane, HY;Lee, CC;Liu, YC;Chang, WH
贡献者:	附設醫院精神醫學部;China Med Univ & Hosp, Dept Psychiat, Taichung 404, Taiwan;China Med Univ & Hosp, Dept Neurol, Taichung 404, Taiwan;Tzu Chi Univ, Dept Psychiat, Hualien, Taiwan
日期:	2005
上传时间:	2010-09-24 14:53:09 (UTC+8)
出版者:	FUTURE MEDICINE LTD
摘要:	Rispericlone and other newer atypical antipsychotics are becoming the mainstay for schizophrenia treatment. Recent studies suggest that the 5-hydroxytryptamine receptor 2A (5-HT2A) gene (HTR2A) T102C and G-1438A polymorphisms may influence treatment response of rispericlone or olanzapine for schizophrenia's negative symptoms (e.g., blunted affect and social withdrawal). In addition, the HTR6 T267C polymorphism has been linked to rispericlone response for positive symptoms (delusions and hallucinations). The dopamine D2 receptor (DRD2) Ser311Cys polymorphism may also play a role in determining rispericlone efficacy for positive, negative and cognitive symptoms, the DRD2 Ins-A2/Del-A1 diplotype may predict better rispericlone response, and the DRD3 Ser311Cys variant may affect general treatment response of several atypical agents. Although investigators have started to explore genetic effects on cognitions of schizophrenia patients receiving antipsychotics, future larger sized pharmacogenetic studies on both psychotic symptoms and cognitive functions are warranted.
關聯:	PHARMACOGENOMICS 6(2):139-149
显示于类别:	[台中附設醫院] 期刊論文

文件中的档案:

没有与此文件相关的档案.

在CMUR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....